NovaMind Connect is similar to YouTube and other sharing sites where users post their mind maps, and others in the community can rate and comment on them and where visitors to the site can view the posted mind maps, and registered users can download files in NovaMind, JPEG, or PDF format. NovaMind offers features such as NovaMind Connect, NovaMind toolbar, Quartz animation, templates, themes, an upgraded graphics library, task management features, and a presentation mode.
USAR NOVAMIND UPDATE
The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable laws.NovaMind is a mind-mapping software which helps users visualize and organize ideas for their business through brainstorming and creative development to organize, remember, communicate and implement ideas. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The reader is cautioned not to place undue reliance on any forward-looking information. Important factors that could cause actual results to differ materially from the Company's expectations including the risks detailed from time to time in the Company's public disclosure. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. All statements other than statements of historical fact included in this release are forward-looking statements that involve risks and uncertainties. This news release contains forward-looking statements. Beyond BNC210, Bionomics has a strategic partnership with Merck & Co., Inc (known as MSD outside the United States and Canada).
USAR NOVAMIND TRIAL
Bionomics' lead drug candidate BNC210, currently in development for initiation of a second phase II trial for the treatment of PTSD, is a novel, proprietary negative allosteric modulator of the alpha-7 (α7) nicotinic acetylcholine receptor. For more information on how Novamind is enhancing mental wellness and guiding people through their entire healing journey, visit novamind.ca.īionomics is a global, clinical stage biopharmaceutical company leveraging its proprietary platform technologies to discover and develop a deep pipeline of best in class, novel drug candidates. Both Cedar Psychiatry and Cedar Clinical Research are wholly owned subsidiaries of Novamind. Novamind provides ketamine-assisted psychotherapy and other novel treatments through its network of Cedar Psychiatry clinics and operates Cedar Clinical Research, a contract research organization specialized in clinical trials and evidence-based research for psychedelic medicine. Novamind is a leading mental health company enabling safe access to psychedelic medicine through a network of clinics, retreats, and clinical research sites. To learn more about the Bionomics study, please visit this link. "This clinical trial leverages CCR's established track record studying novel treatments for PTSD and other difficult to treat mental health conditions." Reid Robison, Chief Medical Officer of Novamind and Principal Investigator at CCR. "We look forward to investigating BNC210 as a potential treatment for PTSD, a condition that is in need of new treatment options," said Dr. Food and Drug Administration (FDA), a process designed to facilitate the development, and expedite the review of drugs to treat serious conditions and fill an unmet medical need. In 2019, BNC210 received a Fast Track Designation from the U.S. PTSD is associated with a wide range of problems, including difficulties at work, social dysfunction and physical health problems. Lifetime and past-year prevalence rates of PTSD among American adults are 8.3 percent and 4.7 percent, respectively 1. The Bionomics study is titled "A phase IIb, randomized, double blind, two arm study to investigate the effects of BNC210 tablet formulation compared to placebo in adults with post-traumatic stress disorder ("PTSD")". (CSE:NM)(OTC PINK:NVMDF)(FSE:HN2) ("Novamind" or the "Company"), a leading mental health company specialized in psychedelic medicine, is pleased to announce that its wholly owned subsidiary, Cedar Clinical Research ("CCR") has been selected as a research site for a clinical trial sponsored by Bionomics Limited ("Bionomics").
TORONTO, ON / ACCESSWIRE / J/ Novamind Inc. Cedar Clinical Research to Host Phase IIb Trial for a Novel PTSD Treatment
0 kommentar(er)
